Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$64 Mln
P/E Ratio
--
P/B Ratio
3.93
Industry P/E
--
Debt to Equity
-0.02
ROE
-13.1 %
ROCE
621.03 %
Div. Yield
0 %
Book Value
--
EPS
-0.46
CFO
$-258.44 Mln
EBITDA
$-295.83 Mln
Net Profit
$-310.27 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Clearside Biomedical (CLSD)
| -11.11 | -11.11 | -8.22 | -36.98 | -19.52 | -14.97 | -- |
|
BSE Sensex*
| 2.53 | 3.64 | 4.52 | 7.45 | 12.03 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Clearside Biomedical (CLSD)
| -18.67 | 4.46 | -59.27 | 0.36 | -5.52 | 171.03 | -84.56 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for... the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. Address: 900 North Point Parkway, Alpharetta, GA, United States, 30005 Read more
President, CEO & Director
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
President, CEO & Director
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Headquarters
Alpharetta, GA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Clearside Biomedical Inc (CLSD) stood at $ 25 Mln as on 31-Dec-24
The share price of Clearside Biomedical Inc (CLSD) is $0.84 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Clearside Biomedical Inc (CLSD) has given a return of -19.52% in the last 3 years.
Clearside Biomedical Inc (CLSD) has a market capitalisation of $ 64 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Clearside Biomedical Inc (CLSD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Clearside Biomedical Inc (CLSD) and enter the required number of quantities and click on buy to purchase the shares of Clearside Biomedical Inc (CLSD).
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. Address: 900 North Point Parkway, Alpharetta, GA, United States, 30005
The CEO & director of Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.. is Clearside Biomedical Inc (CLSD), and CFO & Sr. VP is Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D..
There is no promoter pledging in Clearside Biomedical Inc (CLSD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Clearside Biomedical Inc. (CLSD) | Ratios |
|---|---|
|
Return on equity(%)
|
125.45
|
|
Operating margin(%)
|
-1476.74
|
|
Net Margin(%)
|
-2064.42
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Clearside Biomedical Inc (CLSD) was $0 Mln.
$0.01
(
